Biotalys an agricultural technology company focused on protein-based biocontrol crop protection solutions, and Novozymes, a company focused on biotech, today announced that the companies have entered into a partnership to expand opportunities for Evoca, Biotalys’ first proprietary biocontrol.
The partnership provides that Novozymes will use its expertise and intellectual property rights to explore additional routes for increasing production of the bioactive protein of Evoca, with the option for a possible commercial collaboration for a future generation of the product.
Evoca is a protein-based biofungicide developed on Biotalys’ Agrobody Foundry platform designed to control fungal diseases like Botrytis and powdery mildew in fruits and vegetables. Following 600 independent and company-driven field and greenhouse trials across multiple regions, pathogens and crops, Evoca is expected to obtain approval by the EPA later this year. This is expected to pave the way for the regulatory assessment of Biotalys’ pipeline of product candidates, which includes biofungicides, biobactericides and bio-insecticides based on the Biotalys Agrobody Foundry technology platform.
Under the agreement, Novozymes will explore during an initial term whether it can increase production of the bioactive protein of Evoca in production hosts additional to those currently used by Biotalys. Novozymes will use its expertise and intellectual property to produce a future generation of Evoca that meets certain agreed success criteria. The outcome of this feasibility study can serve as a potential key milestone for Biotalys and Novozymes to enter into development, supply and commercialization agreements for this future generation of Evoca.